JP2018500373A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018500373A5 JP2018500373A5 JP2017534936A JP2017534936A JP2018500373A5 JP 2018500373 A5 JP2018500373 A5 JP 2018500373A5 JP 2017534936 A JP2017534936 A JP 2017534936A JP 2017534936 A JP2017534936 A JP 2017534936A JP 2018500373 A5 JP2018500373 A5 JP 2018500373A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- effective amount
- subject
- therapeutically effective
- primary
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010020707 Hyperparathyroidism primary Diseases 0.000 claims description 16
- 201000000981 Primary Hyperparathyroidism Diseases 0.000 claims description 16
- 208000024891 symptom Diseases 0.000 claims description 15
- 102000003982 Parathyroid hormone Human genes 0.000 claims description 14
- 108090000445 Parathyroid hormone Proteins 0.000 claims description 14
- 239000000199 parathyroid hormone Substances 0.000 claims description 14
- 229960001319 parathyroid hormone Drugs 0.000 claims description 14
- 210000002966 serum Anatomy 0.000 claims description 8
- UHMPCVGLSKFXHR-NFZXMVPNSA-N (1r,3r)-5-[(2e)-2-[(3as,7ar)-1-[(2s)-6-hydroxy-6-methylheptan-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1h-inden-4-ylidene]ethylidene]-2-methylidenecyclohexane-1,3-diol Chemical compound C1(/[C@@H]2CCC([C@]2(CCC1)C)[C@H](CCCC(C)(C)O)C)=C\C=C1C[C@@H](O)C(=C)[C@H](O)C1 UHMPCVGLSKFXHR-NFZXMVPNSA-N 0.000 claims description 6
- 239000007924 injection Substances 0.000 claims description 6
- 238000002347 injection Methods 0.000 claims description 6
- 238000011282 treatment Methods 0.000 claims description 6
- 208000037147 Hypercalcaemia Diseases 0.000 claims description 4
- 239000002552 dosage form Substances 0.000 claims description 4
- 230000000148 hypercalcaemia Effects 0.000 claims description 4
- 208000030915 hypercalcemia disease Diseases 0.000 claims description 4
- 230000001939 inductive effect Effects 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 4
- 230000000699 topical effect Effects 0.000 claims description 4
- 230000000630 rising effect Effects 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 18
- 201000002980 Hyperparathyroidism Diseases 0.000 claims 2
- 230000001568 sexual effect Effects 0.000 claims 1
- 238000000034 method Methods 0.000 description 19
- 238000001802 infusion Methods 0.000 description 2
- 230000002092 calcimimetic effect Effects 0.000 description 1
- VDHAWDNDOKGFTD-MRXNPFEDSA-N cinacalcet Chemical compound N([C@H](C)C=1C2=CC=CC=C2C=CC=1)CCCC1=CC=CC(C(F)(F)F)=C1 VDHAWDNDOKGFTD-MRXNPFEDSA-N 0.000 description 1
- 229960003315 cinacalcet Drugs 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462098119P | 2014-12-30 | 2014-12-30 | |
| US62/098,119 | 2014-12-30 | ||
| US14/710,744 US10369161B2 (en) | 2014-12-30 | 2015-05-13 | Use of 2-methylene-19-NOR-(20S)-1-alpha,25-dihydroxyvitamin D3 to treat primary hyperparathyroidism |
| US14/710,744 | 2015-05-13 | ||
| PCT/US2015/065174 WO2016109155A1 (en) | 2014-12-30 | 2015-12-11 | USE OF 2-METHYLENE-19-NOR-(20S)-1α,25-DIHYDROXYVITAMIN D3 TO TREAT PRIMARY HYPERPARATHYROIDISM |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018500373A JP2018500373A (ja) | 2018-01-11 |
| JP2018500373A5 true JP2018500373A5 (https=) | 2018-09-13 |
Family
ID=56162989
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017534936A Pending JP2018500373A (ja) | 2014-12-30 | 2015-12-11 | 原発性副甲状腺機能亢進症を処置するための２−メチレン−１９−ノル−（２０Ｓ）−１α，２５−ジヒドロキシビタミンＤ３の使用 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US10369161B2 (https=) |
| EP (1) | EP3240548A1 (https=) |
| JP (1) | JP2018500373A (https=) |
| AU (1) | AU2015374467A1 (https=) |
| CA (1) | CA2969335A1 (https=) |
| WO (1) | WO2016109155A1 (https=) |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040043971A1 (en) | 1995-04-03 | 2004-03-04 | Bone Care International, Inc. | Method of treating and preventing hyperparathyroidism with active vitamin D analogs |
| US6242434B1 (en) * | 1997-08-08 | 2001-06-05 | Bone Care International, Inc. | 24-hydroxyvitamin D, analogs and uses thereof |
| US5843928A (en) | 1997-03-17 | 1998-12-01 | Wisconsin Alumni Research Foundation | 2-alkylidene-19-nor-vitamin D compounds |
| US6306844B1 (en) | 1997-03-17 | 2001-10-23 | Wisconsin Alumni Research Foundation | Use of 2α-methyl-19-nor-20(S)-1α, 25-dihydroxyvitamin D3 to increase bone strength |
| US6136799A (en) | 1998-04-08 | 2000-10-24 | Abbott Laboratories | Cosolvent formulations |
| US6673782B2 (en) | 1999-04-29 | 2004-01-06 | Wisconsin Alumni Research Foundation | Treatment of systemic lupus erythematosis |
| JP2003528833A (ja) | 2000-03-27 | 2003-09-30 | ウイスコンシン アラムナイ リサーチ フオンデーシヨン | 腎移植体安定化用のビタミンｄ化合物 |
| MXPA03000406A (es) | 2000-07-14 | 2003-06-06 | Wisconsin Alumni Res Found | Uso de 2-metilen-19-nor-20(s)-1 alfa,25-dihidroxivitamina d3 para incrementar la resistencia de los huesos. |
| US20050124591A1 (en) | 2003-07-29 | 2005-06-09 | Jin Tian | Use of vitamin Ds to treat kidney disease |
| US20060171983A1 (en) | 2003-07-30 | 2006-08-03 | Jin Tian | Use of Vitamin D receptor activators or Vitamin D analogs to treat cardiovascular disease |
| US7704980B2 (en) | 2003-10-08 | 2010-04-27 | Wisconsin Alumni Research Foundation | Treatment of inflammatory bowel disease with 2-methylene-19-nor-vitamin D compounds |
| US7214671B2 (en) | 2004-02-19 | 2007-05-08 | Wisconsin Alumni Research Foundation | Use of 2-methylene-19-nor-20(S)-1α,25-dihydroxyvitamin D3 for the prophylaxis of bone diseases |
| WO2006086613A2 (en) | 2005-02-11 | 2006-08-17 | Wisconsin Alumni Research Foundation | 2-METHYLENE-19-NOR- (20S-24S) - 1α, 25-D IHYDROXYVITAMIN-D2 |
| AU2010281391B2 (en) | 2009-08-03 | 2015-05-07 | Wisconsin Alumni Research Foundation | Method of preventing renal disease and treating symptoms thereof |
| US8604009B2 (en) | 2010-03-23 | 2013-12-10 | Wisconsin Alumni Research Foundation | (20S)-2-methylene-19-nor-22-dimethyl-1α,25-dihydroxyvitamin D3 and (20R)-2-methylene-19-nor-22-dimethyl-1α,25-hydroxyvitamin D3 |
| CN104394871A (zh) | 2012-06-29 | 2015-03-04 | 威斯康星旧生研究基金会 | 2-亚甲基-19-去甲-(20S)-1α,25-二羟基维生素D3治疗继发性甲状旁腺功能亢进的用途 |
-
2015
- 2015-05-13 US US14/710,744 patent/US10369161B2/en not_active Expired - Fee Related
- 2015-12-11 EP EP15817706.3A patent/EP3240548A1/en not_active Withdrawn
- 2015-12-11 WO PCT/US2015/065174 patent/WO2016109155A1/en not_active Ceased
- 2015-12-11 CA CA2969335A patent/CA2969335A1/en not_active Abandoned
- 2015-12-11 JP JP2017534936A patent/JP2018500373A/ja active Pending
- 2015-12-11 AU AU2015374467A patent/AU2015374467A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015096532A5 (https=) | ||
| JP2014139220A5 (https=) | ||
| JP2015522015A5 (https=) | ||
| JP2018505882A5 (https=) | ||
| WO2014205229A8 (en) | Use of high dose pridopidine for treating huntington's disease | |
| JP2012193216A5 (https=) | ||
| JP2017533972A5 (https=) | ||
| JP2016510343A5 (https=) | ||
| JP2018530578A5 (https=) | ||
| JP2020504129A (ja) | 非アルコール性脂肪性肝炎（ｎａｓｈ）および肝線維症のための併用療法 | |
| JP2020502261A5 (https=) | ||
| ZA202000028B (en) | Use of vibegron to treat overactive bladder | |
| RU2015102831A (ru) | ПРИМЕНЕНИЕ 2-МЕТИЛЕН-19-НОР-(20S)-1α, 25-ДИГИДРОКСИВИТАМИНА D3 ДЛЯ ЛЕЧЕНИЯ ВТОРИЧНОГО ГИПЕРПАРАТИРЕОЗА | |
| RU2018146504A (ru) | Лечение внутрипеченочных холестатических заболеваний | |
| JPWO2019241442A5 (https=) | ||
| JP2018529766A5 (https=) | ||
| JP2016505050A5 (https=) | ||
| JP2019507786A5 (https=) | ||
| JP2016537432A5 (https=) | ||
| JP2016515137A5 (https=) | ||
| FI3998067T3 (fi) | Koostumukset ja menetelmät homokystinurian hoitoon | |
| JP2018500375A5 (https=) | ||
| FI3359572T3 (fi) | Menetelmä multippeliskleroosin hoitamiseksi | |
| JP2019507785A5 (https=) | ||
| JP2018500373A5 (https=) |